A new study led by researchers at The University of Texas MD Anderson Cancer Center provides a deeper understanding of the evolution of the tumor microenvironment during gastric cancer progression.
US FDA grants breakthrough therapy status for Nuvalent’s NVL-655
NVL-655 is intended to treat locally advanced or metastatic ALK-positive NSCLC patients previously treated with two or more ALK TKIs. Credit: Sebastian Kaulitzki / Shutterstock.com.